A Multi-center, Two-Part, Single-Arm, Open Label, 25-Week Trial With PRO 140 in Treatment-Experienced HIV-1 Subjects
Latest Information Update: 08 Oct 2025
At a glance
- Drugs Leronlimab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors CytoDyn
Most Recent Events
- 16 Sep 2025 Status changed from suspended to completed.
- 30 Jun 2022 Planned End Date changed from 30 Jun 2022 to 30 Aug 2022.
- 30 Jun 2022 Planned primary completion date changed from 30 Mar 2022 to 30 Jul 2022.